Last reviewed · How we verify

Intra-Lesional MMR Immunotherapy

Abeer Mohamed Abdelaziz Elkholy · Phase 1 active Biologic

Intra-Lesional MMR Immunotherapy is a Biologic drug developed by Abeer Mohamed Abdelaziz Elkholy. It is currently in Phase 1 development. Also known as: MMR Vaccine, Measles-Mumps-Rubella Vaccine, Priorix®.

At a glance

Generic nameIntra-Lesional MMR Immunotherapy
Also known asMMR Vaccine, Measles-Mumps-Rubella Vaccine, Priorix®
SponsorAbeer Mohamed Abdelaziz Elkholy
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intra-Lesional MMR Immunotherapy

What is Intra-Lesional MMR Immunotherapy?

Intra-Lesional MMR Immunotherapy is a Biologic drug developed by Abeer Mohamed Abdelaziz Elkholy.

Who makes Intra-Lesional MMR Immunotherapy?

Intra-Lesional MMR Immunotherapy is developed by Abeer Mohamed Abdelaziz Elkholy (see full Abeer Mohamed Abdelaziz Elkholy pipeline at /company/abeer-mohamed-abdelaziz-elkholy).

Is Intra-Lesional MMR Immunotherapy also known as anything else?

Intra-Lesional MMR Immunotherapy is also known as MMR Vaccine, Measles-Mumps-Rubella Vaccine, Priorix®.

What development phase is Intra-Lesional MMR Immunotherapy in?

Intra-Lesional MMR Immunotherapy is in Phase 1.

Related